Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors FGFR-1 and FGFR-3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). Interferes tumor angiogenesis, growth, and cancer progression.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is established (work in progress)
Diseases for which it is used
- Ovarian cancer
- Soft tissue sarcoma
- Thyroid cancer
Patient drug information
- Pazopanib (Votrient) package insert
- Pazopanib (Votrient) patient drug information (Chemocare)
- Pazopanib (Votrient) patient drug information (UpToDate)
History of changes in FDA indication
- 10/19/2009: Initial FDA approval for the treatment of patients with advanced renal cell carcinoma. (Based on VEG105192)
- 4/26/2012: New indication for patients with advanced soft tissue sarcoma who have received prior chemotherapy. The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. (Based on PALETTE)
History of changes in EMA indication
- 6/14/2010: Initial marketing authorization as Votrient.
Also known as
- Code name: GW786034B
- Brand name: Pazopater, Votrient